

#53

 **EPIGENESIS**  
PHARMACEUTICALS7 Clarke Drive  
Cranbury, New Jersey 08520  
Telephone: (609) 409-6080  
Direct Facsimile: (413) 254-9245  
Main Facsimile: (609) 409-6126**RECEIVED**

JUN 18 2002

TECH CENTER 1600/2900

**FAX COVER SHEET**

To: Dr. Janet Epps

Company: US PTO GAU 1635

Fax No: 703-305-7939

From: Viviana Amzel Date: 6/12/02 Time: \_\_\_\_\_Direct Dial: (409) 609-3035 E-Mail: varnzal@epigene.comPages including this: 46 Ref. No.: USSN 09/093,972 (EPI-00672)**COMMENTS**

Enclosed are the officially filed Amendment and attachments including marked up claims, clean claims, case law cited, and page 50 (marked up and clean). Thank you. Viviana

**CONFIDENTIALITY NOTICE**

The information in this fax transmission and the documents accompanying it contain confidential information belonging to the sender which is legally privileged. The information is intended only for the use of the individuals or entities named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this faxed information is strictly prohibited. If you have received this fax in error, please immediately notify us by telephone to arrange for return of the original documents to us.

SERIAL NO: 08/093,972

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jonathan W. Nyce : Art Unit: 1635  
Serial No.: 09/093,972 : Examiner: Dr. Epps  
Filed: June 9, 1998 : Appl. Ref. No.: EPI-00672

For: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION & TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH BRONCHOCONSTRICTION, ALLERGY(IES) & INFLAMMATION  
JUN 18 2002  
TECH CENTER 1600/2900

AMENDMENT

I hereby certify that this correspondence is being faxed at 703-305-7939, to the Assistant Commissioner for Patents, Washington DC 20231 on June 12, 2002, by Rashida Haji.

SIGNATURE

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir/Madam:

Responsive to the Office Action of January 22, 2002, please amend the above identified patent application as follows.

IN THE SPECIFICATION

Please amend the specification as indicated in the attached page 50.

IN THE CLAIMS

Please delete claims 154-156, and amend the remaining claims as shown in the enclosures.

REMARKSTHE PENDING CLAIMS

Claims 108-131, 133-134, 146, 148, 151-156, 158-159, 161-173, 178-181, 184-189, 191-193, 195-198 and 200-234 are pending in this case, claims 154-156 are being canceled, and various claims are being amended hereby. Accordingly, claims 108-131, 133-134, 146, 148, 151-153, 158-159, 161-173, 178-181, 184-189, 191-193, 195-198 and 200-234 remain pending.